– Q3 total product revenue of $54.1 million, a YoY increase of 107.5%.– Q3 DAXXIFY® revenue of $22.0 million, and first full year revenue post approval of $71.0 million.– Q3 RHA® Collection revenue of $32.1 million, a YoY increase of 23.2%.– In August, DAXXIFY was approved by the FDA for the treatment of cervical dy.
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Revance Therapeutics (NASDAQ:RVNC – Free Report) had its target price decreased by Barclays from $40.00 to $35.00 in a research note published on Monday morning, Benzinga reports. Barclays currently has an overweight rating on the biopharmaceutical company’s stock. Other equities analysts have also issued reports about the company. BNP Paribas upgraded Revance Therapeutics from an […]
First Republic Investment Management Inc. lowered its position in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 3.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 54,126 shares of the biopharmaceutical company’s stock after selling 1,684 shares during the period. First […]
Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seven research firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average […]